

USSN 09/577,468  
Supplemental Amendment  
24 February 2004


### REMARKS

Previously withdrawn claims 5 and 13-19 are herein canceled. The specification was amended at pages 3 and 5 to add a trademark symbol following "Axokine" and to more clearly indicate the chemical nature of the modified CNTF molecule (C17A ΔC15) as well as the informal designation "Ax-15". The designations of "Ax-15," "Ax-2," "Ax-13" are informal terms, not trade names. Support for these amendments is found in the specification at page 13, line 3.

### Conclusion

In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged. The Office action of 26 Sept 2003 set a 3 month period for reply to 26 Dec 2003. This Amendment document is submitted within the response period with a statutory Terminal Disclaimer. Accordingly, the fee due is \$110 under 37 CFR § 1.20(d). If any further fees should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted

  
Valeta Gregg, Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 593-1077 (direct)